Autoimmune Disease News and Research

RSS

Autoimmune Disease is a condition in which the body recognizes its own tissues as foreign and directs an immune response against them.

Accredo Health Group announces a 10-year renewal of its headquarters with Memphis

Accredo Health Group Inc. announced a 10-year renewal of its 240,000-square-foot headquarters at Century Center, positioning the nation's largest specialty pharmacy and a major fixture of Memphis' health care industry for future growth. The General Investment & Development Companies and Accredo agreed to renew all leases for Accredo's five-building campus, effective January 1, 2010.

22 Oct 2009

Progenika to provide blood group genotyping reference laboratory services to ARUP

Progenika, Inc. today announced that it has entered into an agreement with ARUP Laboratories (ARUP) of Salt Lake City, UT, to provide blood group genotyping reference laboratory services to ARUP to determine patient red blood cell antigen profiles when serology has logistic and functional limitations.

22 Oct 2009

RA patients who adhere to their prescription drug regimen have better outcome: Study

Rheumatoid arthritis (RA) patients who regularly adhere to their prescription drug regimen have fewer emergency room and doctor visits and incur lower medical costs, according to research presented today by Medco Health Solutions, Inc. at the American College of Rheumatology's Annual Meeting in Philadelphia.

20 Oct 2009

Human Genome Sciences and GlaxoSmithKline to present Phase 3 trial results of BENLYSTA

Human Genome Sciences, Inc. and GlaxoSmithKline PLC (GSK) today announced the full presentation of results from BLISS-52, the first of two pivotal Phase 3 trials of BENLYSTA™ (belimumab) in seropositive patients with systemic lupus erythematosus (SLE).

20 Oct 2009

Diabetes represents a global health threat

The International Diabetes Federation (IDF) released new data today showing that a staggering 285 million people worldwide have diabetes.

20 Oct 2009

UCB reports on the outcome of Cimzia and MTX treatment for rheumatoid arthritis

UCB today announced data that showed rapid and sustained improvements in ACR20, physical function, pain and fatigue of rheumatoid arthritis (RA) as early as the first week, and inhibition of progression of structural joint damage (seen at week 24) following treatment with Cimzia (certolizumab pegol), together with methotrexate (MTX), was sustained up to 100 weeks.

19 Oct 2009

Scientists find cause for lupuslike disease in mice

Macrophages, the scavenger cells of the body's immune system, are responsible for disposing of dying cells. Stanford University School of Medicine researchers have identified one pathway in this important process in mice that, if disrupted, causes a lupuslike autoimmune disease.

19 Oct 2009

Genentech reports results of ACTEMRA Phase III study for rheumatoid arthritis

Genentech, Inc., a wholly-owned member of the Roche Group, today announced two-year results from a Phase III study, which showed that people with rheumatoid arthritis (RA) who received either a 4 mg/kg or 8 mg/kg dose of ACTEMRA® (tocilizumab), in combination with methotrexate, had no progression of joint damage, (75 and 83 percent, respectively, as assessed by radiograph) compared with people who received methotrexate alone (66 percent).

19 Oct 2009

Preclinical data of carfilzomib and PR-957 inhibitors to be presented at 2009 ACR/ARHP meeting

Proteolix, Inc. today announced that data from preclinical studies of carfilzomib and PR-957 will be presented at the 2009 ACR/ARHP Annual Scientific Meeting on October 16 - 21 in Philadelphia, PA.

19 Oct 2009

Asthma is the most common underlying condition associated with H1N1 Swine Flu: CDC Report

Cannabis Science Inc., an emerging pharmaceutical cannabis company, notes a report by epidemiologists at the Centers for Disease Control and Prevention (CDC) saying that, among people hospitalized with severe cases of the pandemic strain of H1N1 Swine Flu, asthma is by far the most common underlying condition associated with he disease.

19 Oct 2009

Overview of innovative technology for treating ischemic and autoimmune disorders

Pluristem Therapeutics Inc. today announced that it will present at the New England-Israel Life Sciences Summit at the Brandeis International Business School in Waltham, Mass. Zami Aberman, chairman and CEO of Pluristem will present an update on the company and an overview of its technology at 9:40 EDT, Oct 27, 2009.

15 Oct 2009

IMS Health introduces IMS MIDAS Global Biologics

IMS Health, the world’s leading provider of market intelligence to the pharmaceutical and healthcare industries, today announced the launch of IMS MIDAS Global Biologics™, a powerful offering that enables the company’s clients to make more confident decisions as they assess opportunities in the fast-growing, $120 billion worldwide biologics market.

15 Oct 2009

PIKAMAB obtains U.S. patent rights to develop theragnostic product

PIKAMAB, a stratified medicine biopharmaceutical company, announced today that it has secured exclusive rights to two issued U.S. patents from Hospital for Special Surgery, New York. PIKAMAB is developing Lupus TherasightTM, a novel theragnostic product that will eventually help guide the drug development process and patient treatment protocols in the areas of lupus and lupus nephritis.

15 Oct 2009

Lexicon Pharmaceuticals completes public offering of common stock shares

Lexicon Pharmaceuticals, Inc. today announced the completion of its previously-announced public offering of shares of its common stock. The offering included an aggregate of 38,333,332 shares of Lexicon's common stock after the exercise in full by the underwriters of their over-allotment option and by Invus, L.P., Lexicon's largest stockholder, of its associated right to purchase additional shares.

15 Oct 2009

American Recovery and Reinvestment Act funds to support research in numerous health areas

As part of the $5 billion in grants announced by President Obama, the National Institutes of Health has granted Kaiser Permanente more than $54 million over two years through the American Recovery and Reinvestment Act to conduct health research on a multitude of critical public and clinical health areas.

14 Oct 2009

Kaiser Permanente receives $54 million grant from NIH to conduct health research

14 Oct 2009

Psoriasis patients taking immunosuppressive drugs at increased risk of H1N1 flu viruses

People with psoriasis and/or psoriatic arthritis who are taking biologic or non-biologic immunosuppressive medications should receive the inactived forms of both seasonal influenza and H1N1 (swine flu) vaccines as soon as possible, according to a recommendation from the National Psoriasis Foundation.

13 Oct 2009

Plexxikon commences patient dosing in PLX3397 Phase 1 clinical trial

Plexxikon Inc. today announced that dosing of cancer patients with PLX3397 has started in a Phase 1 clinical trial. PLX3397 is a novel, oral investigational drug for treating multiple diseases, including metastatic cancer and rheumatoid arthritis.

9 Oct 2009

More studies needed to compare the efficacy of different biologic drugs for RA, say researchers

More studies that directly compare the effectiveness of different biologic drugs for rheumatoid arthritis (RA) are needed, say Cochrane Researchers. The researchers reviewed all previous Cochrane Systematic Reviews assessing the effectiveness of biologic disease-modifying drugs for treatment of RA and found that although all were very effective, there was little data on direct comparisons between the drugs that could help doctors decide which to prescribe.

7 Oct 2009

Cochrane Systematic Review finds Abatacept effective against rheumatoid arthritis

Abatacept, a member of a new class of drug that targets immune cells to treat rheumatoid arthritis (RA), is effective against RA, according to a new Cochrane Systematic Review. The review examines recent trials to assess safety and efficacy of the drug.

7 Oct 2009

Autoimmune Disease News and Research

Further Reading

Accredo Health Group announces a 10-year renewal of its headquarters with Memphis

Progenika to provide blood group genotyping reference laboratory services to ARUP

RA patients who adhere to their prescription drug regimen have better outcome: Study

Human Genome Sciences and GlaxoSmithKline to present Phase 3 trial results of BENLYSTA

Diabetes represents a global health threat

UCB reports on the outcome of Cimzia and MTX treatment for rheumatoid arthritis

Scientists find cause for lupuslike disease in mice

Genentech reports results of ACTEMRA Phase III study for rheumatoid arthritis

Preclinical data of carfilzomib and PR-957 inhibitors to be presented at 2009 ACR/ARHP meeting

Asthma is the most common underlying condition associated with H1N1 Swine Flu: CDC Report

Overview of innovative technology for treating ischemic and autoimmune disorders

IMS Health introduces IMS MIDAS Global Biologics

PIKAMAB obtains U.S. patent rights to develop theragnostic product

Lexicon Pharmaceuticals completes public offering of common stock shares

American Recovery and Reinvestment Act funds to support research in numerous health areas

Kaiser Permanente receives $54 million grant from NIH to conduct health research

Psoriasis patients taking immunosuppressive drugs at increased risk of H1N1 flu viruses

Plexxikon commences patient dosing in PLX3397 Phase 1 clinical trial

More studies needed to compare the efficacy of different biologic drugs for RA, say researchers

Cochrane Systematic Review finds Abatacept effective against rheumatoid arthritis

Revolutionizing Life Science: An Interview with SCIEX on ASMS, the SCIEX 7500+ System, and AI-Driven Quantitation

From Discovery Biology to ELRIG Chair

Breathing New Life into Diagnostics: Plasmion's SICRIT Technology

Latest News